As a chemosensitizer or synergizer, TAS-116 showed positive results when combined with (1) programmed death-ligand-1 (PD-L1) antibody nivolumab in patients with colorectal cancer and other solid tumors[77]; (2) radiotherapy in cervical and lung cancer cells in vitro and in vivo[78]; (3) proteasome inhibitor bortezomib in multiple myeloma (MM)[79]; and (4) sunitinib in imatinib-resistant gastrointestinal stromal tumors (GIST)[80]. This evidence concerns the gene CD274 and gastrointestinal stromal tumor.